This site provides INTERCEPT product information for Health Care Professionals in the United States. Learn more

Cerus Websites

INTERCEPT® Blood System For Platelets
Pathogen Reduction System

Go Beyond with INTERCEPT Platelets

The INTERCEPT Blood System for Platelets helps protect patients through broad-spectrum transfusion-transmitted infection (TTI) risk reduction* with the inactivation of bacteria, viruses, protozoans, and leukocytes1, while providing earlier release of platelets2,3 and improved value and operational efficiencies.4,5 Find out why hospitals choose platelets treated with the INTERCEPT Blood System (INTERCEPT Platelets) for their patients.

PROTECT PATIENTS*

Proven Safety and Efficacy

Help protect patients with proactive broad-spectrum reduction of transfusion-transmitted infection (TTI) risk and transfusion-associated graft-vs-host disease (TA-GVHD) risk, through the inactivation of bacteria, viruses, parasites, and leukocytes.1

LEARN MORE
IMPROVE AVAILABILITY

Faster Availability with INTERCEPT Platelets

Potentially receive platelets sooner and ready for transfusion with the avoidance of bacterial testing and product holds.2,3

LEARN MORE
DELIVER VALUE

Gain Value and Operational Efficiencies

INTERCEPT Platelets provide one transfusion-ready inventory for all patients, as well as providing waste and cost reduction associated with testing and TTI risks.*4,5

LEARN MORE

You  may also be interested in View all 

Why Blood Safety Matters
Why Blood Safety Matters: An Interview with Dr. Jerry Squires
Read more
Elevate Patient Care
Elevate Patient Care for Hematology-Oncology Patients
Read more
Mechanism of Action
INTERCEPT Blood System Mechanism of Action
Read more
*There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19, and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, please refer to Package Insert.

References:

  1. INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation.
  2. Collier, T. and Chrebtow , V. “Impact of Pathogen Reduction (PR) vs. LVDS Testing on Platelet Availability: A Study Based on Real-World Experience”. AABB 2022. Poster P-IV-8.
  3. Prichard, A.B., et al. “Comparing Usable Shelf-Life of Pathogen Reduced Platelets vs. LVDS Screened Platelets.” AABB 2022. Poster P-IV-2.
  4. Harm SK, et al. Transfusion. 2018 Apr; 58(4):938-942.
  5. 
Ruby KN, et al. Transfusion. 2018 Jul; 58(7):1665-1669.